A Randomized, Double-Blind, Placebo controlled, Parallel Group Study of Patiromer for the Enablement of Spironolactone Use for Blood Pressure Control in Patients with Resistant Hypertension and Chronic Kidney Disease: Evaluation of Safety and Efficacy (AMBER)

Trial Profile

A Randomized, Double-Blind, Placebo controlled, Parallel Group Study of Patiromer for the Enablement of Spironolactone Use for Blood Pressure Control in Patients with Resistant Hypertension and Chronic Kidney Disease: Evaluation of Safety and Efficacy (AMBER)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Patiromer (Primary) ; Spironolactone
  • Indications Hyperkalaemia
  • Focus Therapeutic Use
  • Acronyms AMBER
  • Sponsors Relypsa
  • Most Recent Events

    • 26 Mar 2018 Planned End Date changed from 1 May 2018 to 1 May 2019.
    • 26 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Feb 2019.
    • 15 Mar 2018 According to a Vifor Pharma media release, company expected to conclude at the end of 2018 , with the top-line data from this study at the beginning of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top